High‐mobility group box‐1 in sterile inflammation. (November 2014)

• Record Type: Journal Article
• Authors: Tsung, A.; Tohme, S.; Billiar, T. R.
• Is Part Of: Journal of internal medicine. Volume 276:Number 5(2014:Nov.)
• Page Start: 425
• Page End: 443
• Publication Date: 2014-11
• Subjects: Internal medicine -- Periodicals; Medicine -- Periodicals; 616
• DOI: 10.1111/joim.12276
• Languages: English
• ISSNs: 0954-6820

Abstract

<abstract abstract-type="main" id="joim12276-abs-0001"> <title>Abstract</title> <p>High‐mobility group box 1 (HMGB1) was originally defined as a ubiquitous nuclear protein, but it was later determined that the protein has different roles both inside and outside of cells. Nuclear HMGB1 regulates chromatin structure and gene transcription, whereas cytosolic HMGB1 is involved in inflammasome activation and autophagy. Extracellular HMGB1 has drawn attention because it can bind to related cell signalling transduction receptors, such as the receptor for advanced glycation end products, Toll‐like receptor (TLR)2, TLR4 and TLR9. It also participates in the development and progression of a variety of diseases. HMGB1 is actively secreted by stimulation of the innate immune system, and it is passively released by ischaemia or cell injury. This review focuses on the important role of HMGB1 in the pathogenesis of acute and chronic sterile inflammatory conditions. Strategies that target HMGB1 have been shown to significantly decrease inflammation in several disease models of sterile inflammation, and this may represent a promising clinical approach for treatment of certain conditions associated with sterile inflammation.</p> </abstract>